A Phase 1 Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability, Effect of Food, Palatability, and Safety of Various DNL343 Oral Formulations in Healthy Participants
Latest Information Update: 14 Jun 2021
At a glance
- Drugs DNL 343 (Primary)
- Indications Amyotrophic lateral sclerosis; Dementia
- Focus Pharmacokinetics
- Sponsors Denali Therapeutics Inc
- 10 Jun 2021 Status changed from recruiting to completed.
- 21 Jan 2021 Planned End Date changed from 1 Apr 2021 to 1 Jun 2021.
- 21 Jan 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Jun 2021.